Arbutus reports fourth quarter and year end 2020 financial results and provides corporate update

Ab-729, arbutus' proprietary subcutaneously delivered rnai agent, demonstrates robust and continuous declines in hepatitis b surface antigen (hbsag) in subjects with chronic hepatitis b (hbv) with favorable safety and tolerability data

ABUS Ratings Summary

ABUS Quant Ranking